Overcoming the PEG-addiction: well-defined alternatives to PEG, from structure–property relationships to better defined therapeutics
about
One-pot glovebox-free synthesis, characterization, and self-assembly of novel amphiphilic poly(sarcosine-b-caprolactone) diblock copolymers.Highly defined multiblock copolypeptoids: pushing the limits of living nucleophilic ring-opening polymerization.Poly(2-oxazoline)s as polymer therapeutics.Image-guided tumor surgery: will there be a role for fluorescent nanoparticles?Synthesis of architecturally well-defined nanogels via RAFT polymerization for potential bioapplications.How to modulate the chemical structure of polyoxazolines by appropriate functionalization.Polyoxazolines for nonfouling surface coatings--a direct comparison to the gold standard PEG.Recent developments and perspectives on gene therapy using synthetic vectors.Polymer nanocompartments in broad-spectrum medical applications.Stimuli responsive synthetic polypeptides derived from N-carboxyanhydride (NCA) polymerisation.Smart branched polymer drug conjugates as nano-sized drug delivery systems.Not just for tumor targeting: unmet medical needs and opportunities for nanomedicine.Oxygen-Promoted Suzuki-Miyaura Reaction for Efficient Construction of Biaryls.A block copolymer of zwitterionic polyphosphoester and polylactic acid for drug delivery.Directed interactions of block copolypept(o)ides with mannose-binding receptors: PeptoMicelles targeted to cells of the innate immune system.Synthesis and Characterization of Stimuli-Responsive Star-Like Polypept(o)ides: Introducing Biodegradable PeptoStars.Polypeptide-Based Conjugates as Therapeutics: Opportunities and Challenges.Materials and methods for delivery of biological drugs.Poly(2-hydroxyethyl methacrylate)-b-poly(L-Lysine) cationic hybrid materials for non-viral gene delivery in NIH 3T3 mouse embryonic fibroblasts.Reversible Bioconjugation: Biodegradable Poly(phosphate)-Protein Conjugates.One-pot aqueous synthesis of sub-10 nm responsive nanogels.Glucose-bearing biodegradable poly(amino acid) and poly(amino acid)-poly(ester) conjugates for controlled payload release.Poly(2-oxazoline) hydrogel monoliths via thiol-ene coupling.Poly(2-oxazoline) hydrogels as next generation three-dimensional cell supportsAn amphiphilic graft copolymer-based nanoparticle platform for reduction-responsive anticancer and antimalarial drug delivery.Introducing PeptoPlexes: polylysine-block-polysarcosine based polyplexes for transfection of HEK 293T cells.Detailed characterization of poly(2-ethyl-2oxazoline)s by energy variable collision-induced dissociation study.Poly(2-oxazoline)s as materials for biomedical applications.Modulation of immunogenicity of poly(sarcosine) displayed on various nanoparticle surfaces due to different physical properties.Cisplatin-Rich Polyoxazoline-Poly(aspartic acid) Supramolecular Nanoparticles.Controlled aggregation and cell uptake of thermoresponsive polyoxazoline-grafted superparamagnetic iron oxide nanoparticles.PeptoSomes for Vaccination: Combining Antigen and Adjuvant in Polypept(o)ide-Based Polymersomes.Hydrogen bonded multilayer films based on poly(2-oxazoline)s and tannic acid.Partial hydrolysis of poly(2-ethyl-2-oxazoline) and potential implications for biomedical applications?Synthesis and characterization of chitosan-coated titanate nanotubes: towards a new safe nanocarrier.Macromolecular prodrugs for controlled delivery of ribavirin.Quo vadis nanomedicine?Polyglycerol Surfmers and Surfactants for Direct and Inverse Miniemulsion.A new way to silicone-based peptide polymers.Complexity and simplification in the development of nanomedicines.
P2860
Q30857418-D5245D12-3BC4-4DDE-A63F-507D640D1F3EQ34295271-16CA1824-A45B-4D7E-8DA3-E13F067D4830Q36716915-D7A44089-AD20-4469-864D-F424344DFE74Q36994932-92450922-25C3-4356-A222-219917C6C51AQ37921625-9DBBF0AA-604A-4FD7-9BF1-6B41FEB284F8Q38023781-51D9C343-C9EE-490C-B2C5-1DFEC5E9C3A3Q38045249-B146430E-BEC4-407E-90AF-16E9CD2FAA38Q38074465-2FA4812A-A1F2-41B0-A781-F184D76E4FA6Q38087985-6ECEA4B9-77B7-47FF-8975-0A3B4CDE5AE1Q38103174-152E24B9-F755-4624-9144-146CFAECD163Q38565174-2FBB6133-527B-41D1-A542-EFE798611CDEQ38602136-12CECBDD-A82C-4180-A6B7-687BD015A018Q38632351-CF1DB1AF-3B38-4730-8ECA-498B1F5E64E6Q38848258-ACA972BD-E5E0-45B6-8E57-B21AA32CDA2BQ38923005-9002A273-79BD-4E51-BEF4-BDDD3795742EQ38960778-DD2F1F1E-F284-4A10-AB5B-9DF96524D102Q38983708-8F5F9ED5-B984-48EF-A0C5-5949CFBDF11DQ38987392-BF00A048-7838-4D02-8E01-07615E3CCFDBQ38991403-80705DCD-D07D-4D7B-91D2-1B40264B4DD6Q39108685-6E88CD1F-C770-4050-8E08-604280AD5359Q39140918-ACC963A0-F411-423B-87DC-3D63E341B847Q39252342-88954626-390E-4ACF-A084-D790D4C3378BQ39570317-695E2701-2BB1-4879-91AF-58F541BBD5BCQ40456028-11C5E3AA-E944-4777-8316-7371BDDFA728Q40601818-689E6C3F-DF39-4269-8AC4-154C38F8E774Q42211507-216DECC1-571E-4D52-AA25-28E852C20597Q45774506-A2C2E7EE-66E0-4653-8020-D41B9EC16619Q45856157-FC94EDB1-543E-4AD7-8E89-3A52ED62B26FQ47374953-EAB5823B-8F96-4F58-B2B5-0BDB3B196A05Q47411586-D1F601BA-8540-4D87-8E86-A6F33C5B963BQ48280478-6D8E0940-0B34-4295-A9EC-33FB61B69D09Q48320248-B90E1DF9-A30C-4BA6-88B6-395293417F87Q49042830-BAE3BAD4-817B-4D73-A978-210ABD98228EQ49159919-4369E9C9-68EA-4A00-8659-5E09638031BFQ50094547-5AF06820-3F48-48B0-AFF0-71BD91F621F5Q50547116-8047820F-BA3A-44CF-8537-F82EC9617BE6Q50611624-8350F829-1646-4A2D-8BFD-970251E47C83Q50917000-EDB25DE7-F370-4CB7-A200-A5D245A898AAQ51011612-9BD040AB-8CB1-4C52-847B-736E19D03B68Q53497380-EE6BBC21-BC41-4FAC-A02D-ED1B7782DDA5
P2860
Overcoming the PEG-addiction: well-defined alternatives to PEG, from structure–property relationships to better defined therapeutics
description
article
@en
im Januar 2011 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2011
@uk
name
Overcoming the PEG-addiction: ...... to better defined therapeutics
@en
Overcoming the PEG-addiction: ...... to better defined therapeutics
@nl
type
label
Overcoming the PEG-addiction: ...... to better defined therapeutics
@en
Overcoming the PEG-addiction: ...... to better defined therapeutics
@nl
prefLabel
Overcoming the PEG-addiction: ...... to better defined therapeutics
@en
Overcoming the PEG-addiction: ...... to better defined therapeutics
@nl
P2093
P2860
P356
P1433
P1476
Overcoming the PEG-addiction: ...... to better defined therapeutics
@en
P2093
María J. Vicent
Matthias Barz
Robert Luxenhofer
Rudolf Zentel
P2860
P356
10.1039/C0PY00406E
P577
2011-01-01T00:00:00Z